Advertisement

Topics

Samsung Bioepis' Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency

07:30 EDT 23 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
The positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use will now be referred to the European Commission which will review and decide on the grant of a marketing a...

Other Sources for this Article

Samsung Bioepis Co., Ltd.
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com

NEXT ARTICLE

More From BioPortfolio on "Samsung Bioepis' Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...